Advanced in Chondrosarcoma

Stephanie E. Combs

Ismaninger Str. 22, 
Munich, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Chondrosarcoma
Ismaninger Str. 22, 
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Stephanie Combs practices in Munich, Germany. Ms. Combs is rated as an Advanced expert by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, Mastectomy, and Prostatectomy.

Her clinical research consists of co-authoring 651 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Chondrosarcoma.

Gender
Female

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Other
Study Phase: Not Applicable
Observational Study on Biomarkers in Head and Neck Cancer
Observational Study on Biomarkers in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma
Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma
Enrollment Status: Completed
Publish Date: April 03, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Enrollment Status: Withdrawn
Publish Date: May 17, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial
Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial
Enrollment Status: Completed
Publish Date: May 17, 2018
Intervention Type: Radiation
Study Phase: Not Applicable
View 7 Less Clinical Trials

651 Total Publications

Fluorescence molecular imaging of high-grade gliomas and brain metastases using the RAS70 peptide targeting plasma membrane-bound Hsp70 on tumor cells.
Fluorescence molecular imaging of high-grade gliomas and brain metastases using the RAS70 peptide targeting plasma membrane-bound Hsp70 on tumor cells.
Journal: Journal of neuro-oncology
Published: July 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Combs's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile